Oncolytic Virus Specialist Virttu Biologics Confirms Treatment of First Cohort of Patients in Phase I/II SEPREHVIR Study in Mesothelioma Glasgow, August 27, 2013: Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced that it has treated the first cohort of patients in its Phase I/IIa … (more)
Source: www.topix.com Via newsmixx: home News